Overview
Palynziq (pegvaliase-pqpz) is a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing therapy management.

Coverage Guidelines
Member must meet ALL the following criteria and documentation has been submitted:
- Member has a diagnosis of uncontrolled PKU on current therapy
- Member is at least 18 years of age
- Member has a baseline phenylalanine level of ≥600 micromol/L despite current therapy
- Member has had an inadequate response or adverse reaction or a contraindication to Kuvan
- Member has been educated to recognize signs and symptoms of anaphylaxis, has been prescribed auto-injectable epinephrine and instructed on its appropriate use.

Continuation of Therapy
Reauthorization may be approved upon receipt of documentation evidencing one of the following:
1. 20% reduction from baseline in blood phenylalanine
2. Blood phenylalanine concentrations are 600 micromol/L or less

Limitations
1. Initial approvals may be granted for 33 weeks to allow for induction and titration to 20mg
2. Reauthorizations will be granted for 12 months

References

**Review History**
02/20/19 – Reviewed

**Disclaimer**
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.